Galiximab
- Generic Name
- Galiximab
- Drug Type
- Biotech
- CAS Number
- 357613-77-5
- Unique Ingredient Identifier
- S9OX9692ZB
- Background
Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
- Indication
Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
CAR-T cell therapy has emerged as a promising treatment for Non-Hodgkin Lymphoma (NHL), particularly for patients with chemotherapy-resistant forms of the disease. This article reviews the structure, molecular mechanisms, clinical trial results, and challenges of CAR-T cell-based therapies, focusing on their application in NHL.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath